News Releases

Filter News Releases by year:
2019 | 2018 | 2017 | 2016
Showing results filtered by:
ClEAR ALL
HIV/AIDS
88 Results

September 2019

NIH Bolsters Funding for HIV Implementation Research in High-Burden U.S. Areas

September 05, 2019

The National Institutes of Health has awarded approximately $11.3 million to 23 institutions across the United States to collaborate with community partners to develop locally relevant plans for diagnosing, treating and preventing HIV in areas with high rates of new HIV cases.

July 2019

A woman holds the dapivirine vaginal ring. 

Most Women Use Vaginal Ring for HIV Prevention in Open-Label Study

July 23, 2019

In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling. In addition, the study found that participants appeared to use the ring more in the open-label study than in a previous clinical trial. These and other results of the HIV Open Label Extension (HOPE) study were presented today at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City.

Single pills (brand name Truvada) containing two antiretroviral drugs, emtricitabine (TFC) and tenofovir disoproxyl fumarate (TDF) used for pre-exposure prophylaxis, or PrEP.

PrEP Use High but Wanes after Three Months Among Young African Women

July 23, 2019

In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months. However, PrEP use fell among participants in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored, evidence-based adherence support strategies may be needed to durably engage young African women in consistent PrEP use.

Connection to HIV Care Helps Hardly Reached US Populations Suppress the Virus

July 22, 2019

Gay, bisexual and other men who have sex with men and transgender women with HIV, who are not in care, can be engaged in care when reached and connected with HIV treatment services, according to findings from a clinical trial supported by the National Institutes of Health. Nearly half of the study participants achieved and maintained viral suppression by one year, researchers reported today at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City. 

A man’s hand holding an HIV awareness ribbon

NIH and Partners to Launch HIV Vaccine Efficacy Trial in the Americas and Europe

July 15, 2019

The National Institutes of Health and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people.

Persistent HIV in Central Nervous System Linked to Cognitive Impairment

July 15, 2019

Many people with HIV on antiretroviral therapy (ART) have viral genetic material in the cells of their cerebrospinal fluid (CSF), and these individuals are more likely to experience memory and concentration problems, according to new data published online today in the Journal of Clinical Investigation. A study of 69 individuals on long-term ART found that nearly half of the participants had persistent HIV in cells in their CSF, and 30% of this subset experienced neurocognitive difficulties.

June 2019

micrograph of Mtb bacteria

NIH Launches Large TB Prevention Trial for People Exposed to Multidrug-Resistant TB

June 25, 2019

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.

Scanning electromicrograph of an HIV-infected T cell

NIH HIV Experts Prioritize Research to Achieve Sustained ART-Free HIV Remission

June 06, 2019

Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. 

May 2019

Quote on HIV Vaccine Awareness Day 2019

HIV Vaccine Awareness Day 2019

May 18, 2019

Since the first cases of what would become known as HIV/AIDS were initially reported in 1981, scientists and public health officials have been working to better understand HIV, develop strategies to effectively treat and prevent infection, and bring about an end to the pandemic. This effort remains a critical focus globally and for the United States.

Pill box containing antiretroviral therapy for HIV.

NIH Trial Evaluates Long-acting HIV Medication in People Unable to Adhere to Strict Daily Regimens

May 09, 2019

A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.

April 2019

In Rare Cases, Immune System Fails Despite HIV Suppression

April 18, 2019

Antiretroviral therapy (ART) is usually very effective at suppressing HIV in the body, allowing a person’s immune system to recover by preventing the virus from destroying CD4+ T cells. Scientists have now identified a rare, paradoxical response to ART known as extreme immune decline, or EXID.

Microscopic image of an HIV-infected T cell.

Novel Antibody May Suppress HIV for Up to Four Months

April 17, 2019

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV.

March 2019

Researchers Report High Rate of Viral Suppression Among People New to HIV Care

March 07, 2019

Eighty-six percent of individuals who entered HIV care soon after diagnosis maintained viral suppression after 48 weeks during a clinical trial conducted at four National Institutes of Health (NIH)-funded Centers for AIDS Research (CFARs) across the United States. Participants in the clinical trial, called iENGAGE, achieved viral suppression in an average of just 63 days.

Dr. Samuel Pierre uses a stethoscope to examine a patient’s lungs at the GHESKIO clinic in Port-au-Prince, Haiti.

Tuberculosis Diagnosis in People with HIV Increases Risk of Death Within 10 Years

March 06, 2019

Among people with HIV in Latin America, those diagnosed with tuberculosis (TB) at an initial clinic visit were about twice as likely to die within 10 years as people not initially diagnosed with TB, according to findings from a large observational study. This increased risk persisted despite the availability of TB treatment and mirrored patterns seen previously in HIV-negative populations, according to research supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Close-up of blood from an adult’s finger being captured in a capillary tube for an HIV test

HIV Prevention Study Finds Universal "Test and Treat" Approach Can Reduce New HIV Infections

March 04, 2019

New HIV infections declined by 30 percent in southern African communities where health workers conducted house-to-house voluntary HIV testing, referred people who tested positive to begin HIV treatment according to local guidelines, and offered other proven HIV prevention measures to those who tested negative. Local guidelines evolved during the study from offering HIV treatment based on immune health to offering immediate treatment for all. 

February 2019

Close up of two red AIDS awareness ribbons pinned to white fabric.

NIH Clinical Trial to Track Outcomes of Liver Transplantation from HIV-Positive Donors to HIV-Positive Recipients

February 14, 2019

The first large-scale clinical trial to study liver transplantation between people with HIV has begun at clinical centers across the United States. The HOPE in Action Multicenter Liver Study will determine the safety of this practice by evaluating liver recipients for potential transplant-related and HIV-related complications following surgery. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and follows the 2018 launch of a similar study evaluating kidney transplantation between people with HIV.

Dapivirine vaginal ring and tablets of oral PrEP medication

Study of PrEP and Vaginal Ring for HIV Prevention Begins in Girls and Young Women

February 07, 2019

A clinical trial has begun to examine the safety and use of two HIV prevention tools—oral pre-exposure prophylaxis (PrEP) and a vaginal ring—in adolescent girls and young women in southern Africa. Funded by the National Institutes of Health, the trial is designed to contribute to the delivery of safe, effective and desirable choices of HIV prevention methods for adolescent girls and young women, who are disproportionately affected by the HIV epidemic.

January 2019

Scanning electromicrograph of an HIV-infected T cell

NIH-Supported Scientists Develop Tool to Measure Success of HIV Cure Strategies

January 30, 2019

Scientists funded by the National Institutes of Health have developed a new assay to accurately and easily count the cells that comprise the HIV reservoir, the stubborn obstacle to an HIV cure. This advance will enable researchers who are trying to eliminate the HIV reservoir to clearly understand whether their strategies are working. The research was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.

The Science Is Clear: With HIV, Undetectable Equals Untransmittable

January 10, 2019

In recent years, an overwhelming body of clinical evidence has firmly established the HIV Undetectable = Untransmittable (U=U) concept as scientifically sound, say officials from the National Institutes of Health. U=U means that people living with HIV who achieve and maintain an undetectable viral load—the amount of HIV in the blood—by taking and adhering to antiretroviral therapy (ART) as prescribed cannot sexually transmit the virus to others.

December 2018

A variety of antiretroviral drugs used to treat HIV infection

NIH to Fund HIV Care and Prevention Research in Vulnerable Southern U.S. Communities

December 11, 2018

The National Institute of Allergy and Infectious Diseases will fund a series of collaborations with medical research institutions in the southern United States to test new ways of implementing HIV treatment and prevention tools in counties with some of the highest rates of new HIV cases nationwide. The U.S. South overall has the highest rates of new HIV diagnoses, people living with HIV, and HIV-related deaths of any U.S. region. 

November 2018

An AIDS ribbon depicted with broadly neutralizing antibodies

NIH Statement on World AIDS Day, December 1, 2018

November 30, 2018

Each year on World AIDS Day, we reflect on the remarkable progress that has been made against HIV. Indeed, we have come a long way since the disease now known as AIDS was first reported in 1981. 

Man getting blood drawn for HIV testing

Meeting the Challenge of Engaging Men in HIV Prevention and Treatment

November 29, 2018

A new commentary from National Institutes of Health scientists asserts that engaging men in HIV prevention and care is essential to the goal of ending the HIV pandemic. The article by Adeola Adeyeye, M.D., M.P.A., and David Burns, M.D., M.P.H., of the National Institute of Allergy and Infectious Diseases (NIAID) and Michael Stirratt, Ph.D., of the National Institute of Mental Health (NIMH) also discusses potential solutions.

September 2018

Combination HIV Antibody Infusions Safely Maintain Viral Suppression in Select Individuals

September 26, 2018

A small group of people living with HIV sensitive to two potent anti-HIV broadly neutralizing antibodies (bNAbs)—3BNC117 and 10-1074—tolerated multiple infusions of the antibodies and suppressed HIV for more than 15 weeks after stopping antiretroviral therapy (ART). The new findings, from a pilot clinical trial supported by the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation and others, are reported today in Nature.

Bags of fluid for intravenous (IV) infusions. 

NIH Launches Study to Test Combination Antibody Treatment for HIV Infection

September 20, 2018

A clinical trial testing infusions of combination antibodies in people living with HIV has begun at the National Institutes of Health. The early-phase clinical trial will evaluate whether periodic infusions of two highly potent, HIV-specific, broadly neutralizing antibodies (bNAbs)—3BNC117 and 10-1074—are safe in people living with HIV. The study also will gather preliminary data on how effectively the bNAb infusions, delivered together every two to four weeks, suppress HIV following discontinuation of antiretroviral therapy (ART). 

August 2018

A counselor listens to and advises a client.

Novel Intervention Halves Rate of Death Among People Living with HIV Who Inject Drugs

August 30, 2018

An intervention designed to facilitate treatment for HIV and substance use was associated with a 50 percent reduction in mortality for people living with HIV who inject illicit drugs, a study has found. In addition, the people who received the intervention were nearly twice as likely to report being in treatment for HIV and substance use after one year as those who received their national standard of care. They also were about twice as likely to have suppressed their HIV to undetectable levels after one year.